These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 7753064

  • 21. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals.
    Penney JB, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, Ramos-Arroyo M, Gomez F, Penchaszadeh G, Alvir J.
    Mov Disord; 1990; 5(2):93-9. PubMed ID: 2139171
    [Abstract] [Full Text] [Related]

  • 22. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia.
    Markianos M, Panas M, Kalfakis N, Vassilopoulos D.
    Ann Neurol; 2005 Apr; 57(4):520-5. PubMed ID: 15786456
    [Abstract] [Full Text] [Related]

  • 23. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott MP.
    Mov Disord; 2008 Jul 15; 23(9):1223-7. PubMed ID: 18512767
    [Abstract] [Full Text] [Related]

  • 24. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
    Kenney C, Hunter C, Davidson A, Jankovic J.
    Mov Disord; 2007 Jan 15; 22(1):10-3. PubMed ID: 17078062
    [Abstract] [Full Text] [Related]

  • 25. The capacity of attention and simultaneous perception of objects: a group study of Huntington's disease patients.
    Finke K, Schneider WX, Redel P, Dose M, Kerkhoff G, Müller HJ, Bublak P.
    Neuropsychologia; 2007 Nov 05; 45(14):3272-84. PubMed ID: 17681560
    [Abstract] [Full Text] [Related]

  • 26. A follow-up study of isolated cases of suspected Huntington's disease.
    Bateman D, Boughey AM, Scaravilli F, Marsden CD, Harding AE.
    Ann Neurol; 1992 Mar 05; 31(3):293-8. PubMed ID: 1386209
    [Abstract] [Full Text] [Related]

  • 27. Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype.
    Mancuso M, Kiferle L, Petrozzi L, Nesti C, Rocchi A, Ceravolo R, Orsucci D, Maluccio MR, Bonuccelli U, Filosto M, Siciliano G, Murri L.
    Neurosci Lett; 2008 Oct 17; 444(1):83-6. PubMed ID: 18706972
    [Abstract] [Full Text] [Related]

  • 28. Rate of functional decline in Huntington's disease. Huntington Study Group.
    Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I.
    Neurology; 2000 Jan 25; 54(2):452-8. PubMed ID: 10668713
    [Abstract] [Full Text] [Related]

  • 29. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J.
    Mov Disord; 2006 Nov 25; 21(11):1998-2001. PubMed ID: 16941461
    [Abstract] [Full Text] [Related]

  • 30. Health-related quality of life in Huntington's disease: Which factors matter most?
    Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA.
    Mov Disord; 2009 Mar 15; 24(4):574-8. PubMed ID: 19097181
    [Abstract] [Full Text] [Related]

  • 31. Bradykinesia is not a "systematic" feature of adult-onset Huntington's disease; implications for basal ganglia pathophysiology.
    Fenney A, Jog MS, Duval C.
    Brain Res; 2008 Feb 08; 1193():67-75. PubMed ID: 18177845
    [Abstract] [Full Text] [Related]

  • 32. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.
    Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA.
    Nat Genet; 1993 Aug 08; 4(4):398-403. PubMed ID: 8401589
    [Abstract] [Full Text] [Related]

  • 33. Assessment of coenzyme Q10 tolerability in Huntington's disease.
    Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I.
    Mov Disord; 1996 May 08; 11(3):321-3. PubMed ID: 8723151
    [Abstract] [Full Text] [Related]

  • 34. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
    Vojvodić N, Culjković B, Romac S, Stojković O, Sternić N, Sokić D, Kostić VS.
    Srp Arh Celok Lek; 1998 May 08; 126(3-4):77-82. PubMed ID: 9863360
    [Abstract] [Full Text] [Related]

  • 35. Clinical measurement of mobility and balance impairments in Huntington's disease: validity and responsiveness.
    Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS.
    Gait Posture; 2009 Apr 08; 29(3):433-6. PubMed ID: 19111470
    [Abstract] [Full Text] [Related]

  • 36. Psychiatric features of Huntington's disease: recent approaches and findings.
    Folstein SE, Folstein MF.
    Psychiatr Dev; 1983 Apr 08; 1(2):193-205. PubMed ID: 6232607
    [Abstract] [Full Text] [Related]

  • 37. Two years' follow-up of rivastigmine treatment in Huntington disease.
    de Tommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P.
    Clin Neuropharmacol; 2007 Apr 08; 30(1):43-6. PubMed ID: 17272969
    [Abstract] [Full Text] [Related]

  • 38. [Evolution of locomotion disorders in Huntington's disease].
    Delval A, Krystkowiak P, Blatt JL, Delliaux M, Destée A, Derambure P, Defebvre L.
    Neurophysiol Clin; 2008 Apr 08; 38(2):117-25. PubMed ID: 18423332
    [Abstract] [Full Text] [Related]

  • 39. The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study.
    Youssov K, Dolbeau G, Maison P, Boissé MF, Cleret de Langavant L, Roos RA, Bachoud-Lévi AC.
    Mov Disord; 2013 Dec 08; 28(14):1995-2001. PubMed ID: 24123464
    [Abstract] [Full Text] [Related]

  • 40. Grasping premanifest Huntington's disease - shaping new endpoints for new trials.
    Reilmann R, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, Auer DP, Ringelstein EB, Lange HW.
    Mov Disord; 2010 Dec 15; 25(16):2858-62. PubMed ID: 20818671
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.